Archives of Pharmacal Research

, Volume 33, Issue 11, pp 1789–1795 | Cite as

Adoptive immunotherapy of human gastric cancer with ex vivo expanded T cells

  • Yeon Jin Kim
  • Jaeseung Lim
  • Jong Soon Kang
  • Hwan Mook Kim
  • Hong Kyung Lee
  • Hwa Sun Ryu
  • Jee Youn Kim
  • Jin Tae Hong
  • Youngsoo Kim
  • Sang-Bae Han
Article

Abstract

Surgical resection of gastric cancer has made significant progress, but majority of patients with advanced gastric cancer face relapse and die within five years. In this study, the antitumor activity of ex vivo expanded T cells against the human gastric cancer was evaluated in vitro and in vivo. Human peripheral blood mononuclear cells were cultured with IL-2-containing medium in anti-CD3 antibody-coated flasks for 5 days, followed by incubation in IL-2-containing medium for 9 days. The resulting populations were mostly CD3+ T cells (97%) and comprised 1% CD3CD56+, 36% CD3+CD56+, 11% CD4+, and 80% CD8+. This heterogeneous cell population was also called cytokine-induced killer (CIK) cells. CIK cells strongly produced IFN-γ, moderately TNF-α, but not IL-2 and IL-4. At an effector-target cell ratio of 30:1, CIK cells destroyed 58% of MKN74 human gastric cancer cells, as measured by the 51Cr-release assay. In addition, CIK cells at doses of 3 and 10 million cells per mouse inhibited 58% and 78% of MKN74 tumor growth in nude mouse xenograft assays, respectively. This study suggests that CIK cells may be used as an adoptive immunotherapy for gastric cancer patients.

Key words

Cytokine-induced killer cell Adoptive immunotherapy Human gastric cancer 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Baker, J., Verneris, M. R., Ito, M., Shizuru, J. A., and Negrin, R. S., Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood, 97, 2923–2931 (2001).CrossRefPubMedGoogle Scholar
  2. Brossart, P., Wirths, S., Stuhler, G., Reichardt, V. L., Kanz, L., and Brugger, W., Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood, 96, 3102–3108 (2000).PubMedGoogle Scholar
  3. De Vita, F., Giuliani, F., Orditura, M., Maiello, E., Galizia, G., Di Martino, N., Montemurro, F., Carteni, G., Manzione, L., Romito, S., Gebbia, V., Ciardiello, F., Catalano, G., and Colucci, G., Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). Ann. Oncol., 18, 1354–1358 (2007).CrossRefPubMedGoogle Scholar
  4. Guo, D. L., Dong, M., Wang, L., Sun, L. P., and Yuan, Y., Expression of gastric cancer-associated MG7 antigen in gastric cancer, precancerous lesions and H. pylori-associated gastric diseases. World J. Gastroenterol., 8, 1009–1013 (2002).PubMedGoogle Scholar
  5. Hallissey, M. T., Dunn, J. A., Ward, L. C., and Allum, W. H., The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet, 343, 1309–1312 (1994).CrossRefPubMedGoogle Scholar
  6. Han, S. B., Park, S. H., Jeon, Y. J., Kim, Y. K., Kim, H. M., and Yang, K. H., Prodigiosin blocks T cell activation by inhibiting interleukin-2Ralpha expression and delays progression of autoimmune diabetes and collagen-induced arthritis. J. Pharmacol. Exp. Ther., 299, 415–425 (2001).PubMedGoogle Scholar
  7. Han, S. B., Lee, C. W., Yoon, Y. D., Kang, J. S., Lee, K. H., Yoon, W. K., Kim, Y. K., Lee, K., Park, S. K., and Kim, H. M., Effective prevention of lethal acute graft-versus-host disease by combined immunosuppressive therapy with prodigiosin and cyclosporine A. Biochem. Pharmacol., 70, 1518–1526 (2005).CrossRefPubMedGoogle Scholar
  8. Hoshino, T., Seki, N., Kikuchi, M., Kuramoto, T., Iwamoto, O., Kodama, I., Koufuji, K., Takeda, J., and Itoh, K., HLA class-I-restricted and tumor-specific CTL in tumor-infiltrating lymphocytes of patients with gastric cancer. Int. J. Cancer, 70, 631–638 (1997).CrossRefPubMedGoogle Scholar
  9. Jiang, J., Xu, N., Wu, C., Deng, H., Lu, M., Li, M., Xu, B., Wu, J., Wang, R., Xu, J., and Nilsson-Ehle, P., Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer Res., 26, 2237–2242 (2006).PubMedGoogle Scholar
  10. Kalergis, A. M. and Ravetch, J. V., Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J. Exp. Med., 195, 1653–1659 (2002).CrossRefPubMedGoogle Scholar
  11. Kim, H. M., Kang, J. S., Lim, J., Park, S. K., Lee, K., Yoon, Y. D., Lee, C. W., Lee, K. H., Han, G., Yang, K. H., Kim, Y. J., Kim, Y., and Han, S. B., Inhibition of human ovarian tumor growth by cytokine-induced killer cells. Arch. Pharm. Res., 30, 1464–1470 (2007a).CrossRefPubMedGoogle Scholar
  12. Kim, H. M., Lim, J., Park, S. K., Kang, J. S., Lee, K., Lee, C. W., Lee, K. H., Yun, M. J., Yang, K. H., Han, G., Kwon, S. W., Kim, Y., and Han, S. B., Antitumor activity of cytokine-induced killer cells against human lung cancer. Int. Immunopharmacol., 7, 1802–1807 (2007b).CrossRefPubMedGoogle Scholar
  13. Kim, H. M., Lim, J., Yoon, Y. D., Ahn, J. M., Kang, J. S., Lee, K., Park, S. K., Jeong, Y. J., Kim, J. M., Han, G., Yang, K. H., Kim, Y. J., Kim, Y., and Han, S. B., Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma. Int. Immunopharmacol., 7, 1793–1801 (2007c).CrossRefPubMedGoogle Scholar
  14. Kondo, K., Kaneko, T., Baba, M., and Konno, H., VEGF-C and VEGF-A synergistically enhance lymph node metastasis of gastric cancer. Biol. Pharm. Bull., 30, 633–637 (2007).CrossRefPubMedGoogle Scholar
  15. Kono, K., Rongcun, Y., Charo, J., Ichihara, F., Celis, E., Sette, A., Appella, E., Sekikawa, T., Matsumoto, Y., and Kiessling, R., Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. Int. J. Cancer, 78, 202–208 (1998).CrossRefPubMedGoogle Scholar
  16. Kornacker, M., Moldenhauer, G., Herbst, M., Weilguni, E., Tita-Nwa, F., Harter, C., Hensel, M., and Ho, A. D., Cytokine-induced killer cells against autologous CLL: direct cytotoxic effects and induction of immune accessory molecules by interferon-gamma. Int. J. Cancer, 119, 1377–1382 (2006).CrossRefPubMedGoogle Scholar
  17. Lim, L., Michael, M., Mann, G. B., and Leong, T., Adjuvant therapy in gastric cancer. J. Clin. Oncol., 23, 6220–6232 (2005).CrossRefPubMedGoogle Scholar
  18. Lu, P. H. and Negrin, R. S., A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J. Immunol., 153, 1687–1696 (1994).PubMedGoogle Scholar
  19. Moehler, M., Lyros, O., Gockel, I., Galle, P. R., and Lang, H., Multidisciplinary management of gastric and gastroesophageal cancers. World J. Gastroenterol., 14, 3773–3780 (2008).CrossRefPubMedGoogle Scholar
  20. Nie, Y., Wu, K., Yang, J., Tian, F., Li, L., Chen, B., and Fan, D., Induction of T lymphocytes specific to human gastric cancer using HLA-A matched allogeneic gastric tumor cells. J. Immunother., 26, 403–411 (2003).CrossRefPubMedGoogle Scholar
  21. Nishimura, R., Baker, J., Beilhack, A., Zeiser, R., Olson, J. A., Sega, E. I., Karimi, M., and Negrin, R. S., In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood, 112, 2563–2574 (2008).CrossRefPubMedGoogle Scholar
  22. Ohshita, A., Yamaguchi, Y., Minami, K., Okita, R., and Toge, T., Generation of tumor-reactive effector lymphocytes using tumor RNA-introduced dendritic cells in gastric cancer patients. Int. J. Oncol., 28, 1163–1171 (2006).PubMedGoogle Scholar
  23. Okada, N., Cell delivery system: a novel strategy to improve the efficacy of cancer immunotherapy by manipulation of immune cell trafficking and biodistribution. Biol. Pharm. Bull., 28, 1543–1550 (2005).CrossRefPubMedGoogle Scholar
  24. Sakuramoto, S., Sasako, M., Yamaguchi, T., Kinoshita, T., Fujii, M., Nashimoto, A., Furukawa, H., Nakajima, T., Ohashi, Y., Imamura, H., Higashino, M., Yamamura, Y., Kurita, A., and Arai, K., Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N. Engl. J. Med., 357, 1810–1820 (2007).CrossRefPubMedGoogle Scholar
  25. Sasako, M., Principles of surgical treatment for curable gastric cancer. J. Clin. Oncol., 21, 274s–275s (2003).CrossRefPubMedGoogle Scholar
  26. Shida, D., Kitayama, J., Mori, K., Watanabe, T., and Nagawa, H., Transactivation of epidermal growth factor receptor is involved in leptin-induced activation of janus-activated kinase 2 and extracellular signal-regulated kinase 1/2 in human gastric cancer cells. Cancer Res., 65, 9159–9163 (2005).CrossRefPubMedGoogle Scholar
  27. Sun, S., Li, X. M., Li, X. D., and Yang, W. S., Studies on inducing apoptosis effects and mechanism of CIK cells for MGC-803 gastric cancer cell lines. Cancer Biother. Radiopharm., 20, 173–180 (2005).CrossRefPubMedGoogle Scholar
  28. Takayama, T., Sekine, T., Makuuchi, M., Yamasaki, S., Kosuge, T., Yamamoto, J., Shimada, K., Sakamoto, M., Hirohashi, S., Ohashi, Y., and Kakizoe, T., Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet, 356, 802–807 (2000).CrossRefPubMedGoogle Scholar
  29. Thorne, S. H., Negrin, R. S., and Contag, C. H., Synergistic antitumor effects of immune cell-viral biotherapy. Science, 311, 1780–1784 (2006).CrossRefPubMedGoogle Scholar
  30. Wang, W., Epler, J., Salazar, L. G., and Riddell, S. R., Recognition of breast cancer cells by CD8+ cytotoxic T-cell clones specific for NY-BR-1. Cancer Res., 66, 6826–6833 (2006).CrossRefPubMedGoogle Scholar
  31. Wu, C., Jiang, J., Shi, L., and Xu, N., Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res., 28, 3997–4002 (2008).PubMedGoogle Scholar
  32. Wu, K., Nie, Y., Guo, C., Chen, Y., Ding, J., and Fan, D., Molecular basis of therapeutic approaches to gastric cancer. J. Gastroenterol. Hepatol., 24, 37–41 (2009).CrossRefPubMedGoogle Scholar
  33. Wu, Y., Wang, L., and Zhang, Y., Dendritic cells as vectors for immunotherapy of tumor and its application for gastric cancer therapy. Cell. Mol. Immunol., 1, 351–356 (2004).PubMedGoogle Scholar
  34. Yang, X. J., Huang, J. A., Lei, W., Zhu, Y. B., and Zhang, X. G., Antitumor effects of cocultured dendritic cells and cytokine-induced killer cells on lung cancer in vitro and in vivo. Ai Zheng, 25, 1329–1333 (2006).PubMedGoogle Scholar

Copyright information

© The Pharmaceutical Society of Korea and Springer Netherlands 2010

Authors and Affiliations

  • Yeon Jin Kim
    • 1
  • Jaeseung Lim
    • 2
  • Jong Soon Kang
    • 3
  • Hwan Mook Kim
    • 3
  • Hong Kyung Lee
    • 1
  • Hwa Sun Ryu
    • 1
  • Jee Youn Kim
    • 1
  • Jin Tae Hong
    • 1
  • Youngsoo Kim
    • 1
  • Sang-Bae Han
    • 1
  1. 1.College of Pharmacy and Medical Research Center (CICT)Chungbuk National UniversityCheongjuKorea
  2. 2.Innocell Ltd.SJ TechnovilleSeoulKorea
  3. 3.Korea Research Institute of Bioscience and BiotechnologyOchangKorea

Personalised recommendations